Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemia

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemia

Immunotherapy for frontline treatment of ALL: inotuzumab ozogamicin and blinatumomabПодробнее

Immunotherapy for frontline treatment of ALL: inotuzumab ozogamicin and blinatumomab

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALLПодробнее

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALL

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicin

Elderly ALL advances: inotuzumab ozogamicin plus mini-hyper-CVDПодробнее

Elderly ALL advances: inotuzumab ozogamicin plus mini-hyper-CVD

Novel ALL treatment strategies: inotuzumab ozogamicinПодробнее

Novel ALL treatment strategies: inotuzumab ozogamicin

INO-VATE trial of inotuzumab ozogamicin: response, efficacy and safety resultsПодробнее

INO-VATE trial of inotuzumab ozogamicin: response, efficacy and safety results

Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy in Older Patients with ALLПодробнее

Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy in Older Patients with ALL

Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?Подробнее

Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?

Inotuzumab as a potential treatment for elderly patients with ALLПодробнее

Inotuzumab as a potential treatment for elderly patients with ALL